Nasdaq

Iveric Bio Announces Positive Topline Data from Zimura® GATHER2 Phase 3 Clinical Trial in ...

- Primary Endpoint Met with 14.3% Reduction (p-value = 0.0064) in Mean Rate of Growth (Slope) in GA Area Over 12 Months Using Square Root Transformation; 17.7% Reduction (p-value = 0.0039) Using ...